05
JUN
2022

Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program

Posted By :
Comments : Off
BETHESDA, Md., June 5, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company’s DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the...
Read More
10
MAY
2022

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma

Posted By :
Comments : Off
For immediate release on May 10, 2022 Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well BETHESDA, Md., May 10, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled “Autologous Tumor Lysate-Loaded...
Read More
04
MAY
2022

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

Posted By :
Comments : Off
BETHESDA, Md., May 4, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled “Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma” will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences....
Read More
17
FEB
2022

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

Posted By :
Comments : Off
BETHESDA, Md., February 17, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK. This milestone follows approval by the UK Medicines and Healthcare Products...
Read More
21
DEC
2021

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

Posted By :
Comments : Off
BETHESDA, Md., December 21, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility. The MHRA license approval enables the...
Read More